In vitro activities of fleroxacin, cefetamet, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against rare members of the family Enterobacteriaceae primarily of human (clinical) origin | Zendy

P. Hohl | Zendy; J Lüthy-Hottenstein | Zendy; J. Zollinger-Iten | Zendy; Martin Altwegg | Zendy

Open Access

In vitro activities of fleroxacin, cefetamet, ciprofloxacin, ceftriaxone, trimethoprim-sulfamethoxazole, and amoxicillin-clavulanic acid against rare members of the family Enterobacteriaceae primarily of human (clinical) origin

Author(s) -

P. Hohl,

J Lüthy-Hottenstein,

J. Zollinger-Iten,

Martin Altwegg

Publication year - 1990

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.34.8.1605

Subject(s) - fleroxacin , ciprofloxacin , ceftriaxone , amoxicillin , microbiology and biotechnology , enterobacteriaceae , trimethoprim , clavulanic acid , antibacterial agent , sulfamethoxazole , cefotaxime , antibiotics , chemistry , biology , ofloxacin , biochemistry , escherichia coli , gene

Fleroxacin and cefetamet were evaluated in vitro against 38 infrequently encountered species (250 strains) of the family Enterobacteriaceae and compared with four established compounds. For all the strains tested, the fleroxacin MIC was less than or equal to 0.5 mg/liter, and for 98% of strains the cefetamet MIC was less than or equal to 8 mg/liter; even though the two new compounds did not quite reach the activities (on a weight-by-weight basis) of ciprofloxacin and ceftriaxone, respectively, they nonetheless clearly surpassed trimethoprim-sulfamethaxazole and amoxicillin-clavulanic acid. The very potent new oral compounds tested in this study appear to be promising for the treatment of clinically relevant infections due to uncommon species of Enterobacteriaceae.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research